Pure Global

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis - Trial NCT05491603

Access comprehensive clinical trial information for NCT05491603 through Pure Global AI's free database. This Phase 2 trial is sponsored by DermBiont, Inc. and is currently Suspended. The study focuses on Onychomycosis. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05491603
Phase 2
Suspended
biological
Trial Details
ClinicalTrials.gov • NCT05491603
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis
An Observer-Blinded, Randomized, Aqueous Gel-Controlled Trial of the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis

Study Focus

Onychomycosis

DBI-001

Interventional

biological

Sponsor & Location

DermBiont, Inc.

Encino,New Brighton,Portland,Austin,Mill Creek, United States of America

Timeline & Enrollment

Phase 2

Oct 01, 2022

Nov 30, 2023

60 participants

Primary Outcome

Change in percentage of involved great toenail(s),Changes in signs and symptoms of Onychomycosis

Summary

This is a randomized, observer-blinded, Aqueous Gel-controlled trial examining the safety and
 efficacy of daily application of DBI-001 Gel vs. DBI-002 Gel vs. Aqueous Gel for 24
 consecutive weeks in subjects with onychomycosis.

ICD-10 Classifications

Onychogryphosis
Chromomycosis, unspecified
Onycholysis
Actinomycosis
Blastomycosis

Data Source

ClinicalTrials.gov

NCT05491603

Non-Device Trial